Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. [electronic resource]
Producer: 20121025Description: 1202-9 p. digitalISSN:- 1528-0020
- Adult
- Aged
- Aged, 80 and over
- Case-Control Studies
- Clinical Trials, Phase I as Topic -- statistics & numerical data
- Clinical Trials, Phase II as Topic -- statistics & numerical data
- Clinical Trials, Phase III as Topic -- statistics & numerical data
- Cohort Studies
- Female
- Follow-Up Studies
- Humans
- Janus Kinase 1 -- antagonists & inhibitors
- Janus Kinase 2 -- antagonists & inhibitors
- Male
- Middle Aged
- Nitriles
- Primary Myelofibrosis -- diagnosis
- Protein Kinase Inhibitors -- therapeutic use
- Pyrazoles -- therapeutic use
- Pyrimidines
- Randomized Controlled Trials as Topic -- statistics & numerical data
- Survival Analysis
- Survivors -- statistics & numerical data
- Treatment Outcome
- Assessment of Medication Adherence
No physical items for this record
Publication Type: Comparative Study; Evaluation Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.